Canaccord Genuity Group Cuts Stoke Therapeutics (NASDAQ:STOK) Price Target to $58.00

Stoke Therapeutics (NASDAQ:STOK) had its price objective trimmed by Canaccord Genuity Group from $60.00 to $58.00 in a report issued on Tuesday, Marketbeat.com reports. The firm currently has a buy rating on the stock.

Several other equities research analysts have also commented on the stock. Chardan Capital reiterated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday. The Goldman Sachs Group started coverage on Stoke Therapeutics in a report on Monday, July 13th. They issued a “buy” rating and a $44.00 target price for the company. BTIG Research reaffirmed a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research report on Monday, May 11th. Finally, Weiss Ratings lowered Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a report on Monday, May 11th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Stoke Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $43.00.

Stoke Therapeutics Price Performance

STOK opened at $31.93 on Tuesday. Stoke Therapeutics has a 1 year low of $12.86 and a 1 year high of $40.22. The company has a market capitalization of $2.06 billion, a price-to-earnings ratio of -9.56 and a beta of 1.20. The firm’s fifty day moving average price is $30.41 and its two-hundred day moving average price is $32.05.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The firm had revenue of $9.32 million for the quarter, compared to the consensus estimate of $4.89 million. As a group, equities analysts anticipate that Stoke Therapeutics will post -3.41 EPS for the current year.

Insider Buying and Selling

In related news, General Counsel Jonathan Allan sold 1,457 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total value of $43,637.15. Following the sale, the general counsel owned 18,086 shares of the company’s stock, valued at approximately $541,675.70. The trade was a 7.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Barry Ticho sold 7,176 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $29.04, for a total value of $208,391.04. Following the completion of the transaction, the insider owned 20,422 shares in the company, valued at approximately $593,054.88. The trade was a 26.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 10,428 shares of company stock worth $306,919 in the last ninety days. 9.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in STOK. RTW Investments LP increased its holdings in Stoke Therapeutics by 8.3% in the 4th quarter. RTW Investments LP now owns 5,546,856 shares of the company’s stock worth $176,057,000 after acquiring an additional 423,331 shares during the last quarter. Redmile Group LLC raised its stake in Stoke Therapeutics by 3.2% in the 1st quarter. Redmile Group LLC now owns 4,164,120 shares of the company’s stock valued at $135,584,000 after acquiring an additional 130,050 shares during the period. Morgan Stanley lifted its holdings in Stoke Therapeutics by 0.3% during the fourth quarter. Morgan Stanley now owns 3,546,158 shares of the company’s stock valued at $112,555,000 after purchasing an additional 9,108 shares during the last quarter. State Street Corp lifted its holdings in Stoke Therapeutics by 75.2% during the fourth quarter. State Street Corp now owns 2,498,049 shares of the company’s stock valued at $79,288,000 after purchasing an additional 1,072,176 shares during the last quarter. Finally, BVF Inc. IL boosted its position in Stoke Therapeutics by 36.7% during the fourth quarter. BVF Inc. IL now owns 2,265,674 shares of the company’s stock worth $71,912,000 after purchasing an additional 608,578 shares during the period.

Key Stoke Therapeutics News

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target to $40 and maintained an “outperform” rating, while Chardan Capital reiterated “buy” with a $35 target. Canaccord retained a “buy” rating despite lowering its target to $58. The broader analyst consensus remains “Moderate Buy,” with an average target of $43. Wedbush price-target update
• Positive Sentiment: Investors continue to focus on Stoke’s pipeline. Management plans to submit a rolling NDA for zorevunersen in the first quarter of 2027 for SCN1A-related Dravet syndrome, while continuing development of STK-002. Approximately $420 million in cash could support these programs and potential launch preparations. Pipeline and NDA outlook
• Neutral Sentiment: Stoke is scheduled to present at the Canaccord Genuity 46th Annual Growth Conference, giving management an opportunity to provide updates on its clinical and regulatory plans. Conference presentation announcement
• Negative Sentiment: HC Wainwright cut its EPS forecasts across 2026–2028: FY2026 to a loss of $3.35 per share from $3.09, FY2027 to a loss of $2.55 from $2.05, and FY2028 to a loss of $1.78 from $0.67. It also lowered quarterly estimates to losses of $0.81 per share. These revisions point to slower progress toward profitability. HC Wainwright earnings estimates
• Negative Sentiment: Stoke’s second-quarter loss of $0.93 per share exceeded the expected loss of $0.80, although revenue of approximately $9.33 million surpassed estimates. The company remains deeply unprofitable, increasing investor sensitivity to cash use and development execution. Second-quarter earnings summary
• Negative Sentiment: Director Barry Ticho sold 7,176 shares for approximately $208,000, reducing his stake by 26%. The sale was conducted under a pre-arranged Rule 10b5-1 plan, which limits its significance but may still weigh modestly on sentiment. SEC insider-sale filing

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.